ClinicalTrials.gg
CompletedNCT02569996Updated Dec 10, 2015Results posted

A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular Lymphoma

A Phase 3 interventional study of Rituximab in Lymphoma, Follicular, sponsored by Hoffmann-La Roche. Completed at 21 sites in Hungary. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-12-10.

Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
124
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.

Enrollment
42nd of 188
124 · median 48
Started
2005
with 12 others
Phase 3
35 of 194
2 open now
Registered
164th of 194
by date
Lead sponsor
4 of 194
Hoffmann-La Roche

Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 42nd largest by enrollment of the 188 interventional ones that give a count, is one of 13 that started in 2005, is one of 35 in phase 3, and was the 164th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies testing rituximab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

This study will evaluate the efficacy, safety, and tolerability of long-term maintenance therapy with rituximab in participants with advanced follicular lymphoma who have had a positive response to first-line treatment with a rituximab-containing regimen. The anticipated time on study treatment is 2 years, and the target sample size is 124 individuals.

03

Conditions studied

  • Lymphoma, Follicular
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult participants greater than (>) 18 years of age
  • confirmed follicular lymphoma Grade 1, 2, or 3a with lymph node within 4 months of induction treatment
  • No previous anti-lymphoma treatment before induction chemotherapy (-treated participants only are eligible)
  • Verified complete or partial remission after first-line induction therapy including rituximab

Exclusion criteria

Exclusion Criteria:

  • Grade 3b follicular lymphoma
  • Transformation to high-grade lymphoma (except to Grade 3a) of previously existing follicular lymphoma
  • Presence of central nervous system lymphoma
  • Acquired immunodeficiency syndrome-related lymphoma
  • Other primary (other than squamous cell cancer of the skin or in situ cancer of the cervix) for which the participant has not been disease-free for greater than or equal to (>=) 5 years
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
124 participants (actual)

Study arms

  • Experimental
    Rituximab

    Participants will receive rituximab 375 milligrams per meter square (mg/m\^2) every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.

    Drug: Rituximab

Interventions

  • Rituximab will be administered at 375 mg/m\^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.

    Also known as: MabThera/Rituxan

06

What researchers measure

Primary outcomes

  1. Event-free Survival

    Event-free survival (EFS) was defined as the time from baseline (Week 0) to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first. Mean EFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population (patients who received at least one maintenance MabThera infusion) was used for this analysis.

    Time frame: From randomization to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first, assessed up to 5 years

Secondary outcomes

  1. Number of Participants With Adverse Events (AEs)

    An adverse event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage, or results in death

    Time frame: Up to 27 months

  2. Overall Survival (OS)

    Overall survival, defined as the time between baseline (Week 0) and the date of death irrespective of the cause of death. Mean OS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population was used for this analysis.

    Time frame: From randomization until death, assessed up to 5 years

  3. Time to Progression (TTP)

    Time to progression (TTP) defined as time from baseline to disease progression or relapse, death from the follicular lymphoma or institution of a new regimen because of the follicular lymphoma. Mean TTP was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population was used for this analysis.

    Time frame: From baseline (Week 0) to disease progression, relapse, death from the follicular lymphoma or institution of a new regimen, whichever occurs first, assessed up to 5 years

  4. Time to Next Anti-lymphoma Treatment (TTNLT)

    Time to next anti-lymphoma treatment (TTNLT) defined as time from baseline to institution of a new antilymphoma regimen (including chemo-, radio- or immunotherapies). Mean TTNLT was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.

    Time frame: From baseline (Week 0) to institution of a new antilymphoma regimen, assessed up to 5 years

  5. Duration of Response (DR)

    Duration of Response (DR) defined as time from first documented response to induction treatment to relapse or progression or death from the follicular lymphoma. Mean DR was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.

    Time frame: From first documented response to induction treatment to relapse or progression or death, assessed up to 5 years

  6. Disease-free Survival (DFS)

    Disease free survival (DFS) being defined as time from first documented complete response to induction treatment to relapse or progression or death from the follicular lymphoma. Mean DFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.

    Time frame: From first documented complete response to induction treatment to relapse or progression or death, whichever occurs first, assessed up to 5 years

07

Results

Posted Dec 10, 2015

Participant flow

This study was conducted between 08 July 2005 to 12 Aug 2013 at 15 sites in Hungary.

Participant flow — Overall Study
MilestoneRituximab
Started124
Completed69
Not completed55
Withdrew: Adverse event6
Withdrew: Physician decision3
Withdrew: Progression of the disease18
Withdrew: New anti-lymphoma treatment1
Withdrew: Non-compliance9
Withdrew: Withdrawal by subject5
Withdrew: Lost to follow-up5
Withdrew: Complete remission7
Withdrew: Unknown reason1

Outcome measures

PrimaryEvent-free Survival

Event-free survival (EFS) was defined as the time from baseline (Week 0) to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first. Mean EFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population (patients who received at least one maintenance MabThera infusion) was used for this analysis.

Time frame:
From randomization to the time to progression, relapse, death from any cause, or institution of a new treatment, whichever occurs first, assessed up to 5 years
Reported as:
Mean · months
Event-free Survival
monthsRituximab
Event-free Survival53.944 (50.242 to 57.647)
SecondaryNumber of Participants With Adverse Events (AEs)

An adverse event (AE) was considered any unfavorable and unintended sign, symptom, or disease associated with the use of the study drug, whether or not considered related to the study drug. A serious adverse event (SAE) was defined as any untoward medical occurrence that is life-threatening, requires inpatient hospitalization or causes prolongation of existing hospitalization, results in persistent or significant disability/incapacity, congenital anomaly/birth defect, requires intervention to prevent permanent impairment or damage, or results in death

Time frame:
Up to 27 months
Reported as:
Number · participants
Number of Participants With Adverse Events (AEs)
participantsRituximab
SAEs14
Non serious AEs32
SecondaryOverall Survival (OS)

Overall survival, defined as the time between baseline (Week 0) and the date of death irrespective of the cause of death. Mean OS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population was used for this analysis.

Time frame:
From randomization until death, assessed up to 5 years
Reported as:
Mean · months
Overall Survival (OS)
monthsRituximab
Overall Survival (OS)72.959 (70.303 to 75.616)
SecondaryTime to Progression (TTP)

Time to progression (TTP) defined as time from baseline to disease progression or relapse, death from the follicular lymphoma or institution of a new regimen because of the follicular lymphoma. Mean TTP was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval. ITT population was used for this analysis.

Time frame:
From baseline (Week 0) to disease progression, relapse, death from the follicular lymphoma or institution of a new regimen, whichever occurs first, assessed up to 5 years
Reported as:
Mean · months
Time to Progression (TTP)
monthsRituximab
Time to Progression (TTP)56.024 (52.532 to 59.516)
SecondaryTime to Next Anti-lymphoma Treatment (TTNLT)

Time to next anti-lymphoma treatment (TTNLT) defined as time from baseline to institution of a new antilymphoma regimen (including chemo-, radio- or immunotherapies). Mean TTNLT was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.

Time frame:
From baseline (Week 0) to institution of a new antilymphoma regimen, assessed up to 5 years
Reported as:
Mean · months
Time to Next Anti-lymphoma Treatment (TTNLT)
monthsRituximab
Time to Next Anti-lymphoma Treatment (TTNLT)59.236 (56.318 to 62.153)
SecondaryDuration of Response (DR)

Duration of Response (DR) defined as time from first documented response to induction treatment to relapse or progression or death from the follicular lymphoma. Mean DR was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.

Time frame:
From first documented response to induction treatment to relapse or progression or death, assessed up to 5 years
Reported as:
Mean · months
Duration of Response (DR)
monthsRituximab
Duration of Response (DR)63.159 (59.29 to 67.029)
SecondaryDisease-free Survival (DFS)

Disease free survival (DFS) being defined as time from first documented complete response to induction treatment to relapse or progression or death from the follicular lymphoma. Mean DFS was estimated by the Kaplan-Meier estimation and provided with their 95% confidence interval.

Time frame:
From first documented complete response to induction treatment to relapse or progression or death, whichever occurs first, assessed up to 5 years
Reported as:
Mean · months
Disease-free Survival (DFS)
monthsRituximab
Disease-free Survival (DFS)66.737 (63.808 to 69.666)

Adverse events

Collected over Up to 27 months. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab—14/124 (11.3%)3/124 (2.4%)
Most frequent serious events
Showing 10 of 24
Most frequent serious events
EventRituximab
PneumoniaRespiratory, thoracic and mediastinal disorders2/124
AgranulocytosisBlood and lymphatic system disorders1/124
Febrile neutropeniaBlood and lymphatic system disorders1/124
NeutropeniaBlood and lymphatic system disorders1/124
Abdominal discomfortGastrointestinal disorders1/124
DiarrhoeaGastrointestinal disorders1/124
Gastric ulcerGastrointestinal disorders1/124
Oral disorderGastrointestinal disorders1/124
OedemaGeneral disorders1/124
Acute hepatitis BInfections and infestations1/124
Most frequent other events
Most frequent other events
EventRituximab
Diabetes mellitusEndocrine disorders3/124

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Rituximab
<=18 years0
Between 18 and 65 years102
>=65 years22
Age, Continuous
Age, Continuous(years)Rituximab
Median53 (26 to 81)
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab
Female84
Male40
08

Study locations

21 sites
  • Budapest, 1071, Hungary
  • Budapest, 1083, Hungary
  • Budapest, 1085, Hungary
  • Budapest, 1088, Hungary
  • Budapest, 1122, Hungary
  • Budapest, 1135, Hungary
  • Debrecen, 4032, Hungary
  • Gyor, 9024, Hungary
  • Gyula, 5700, Hungary
  • Kaposvar, 7400, Hungary
  • Miskolc, 3529, Hungary
  • Nyíregyháza, 4400, Hungary
  • Pecs, 7624, Hungary
  • Szeged, 6720, Hungary
  • Szekszard, 7100, Hungary
  • Szolnok, 5004, Hungary
  • Szombathely, 9700, Hungary
  • Székesfehérvár, 8000, Hungary
  • Tatabánya, 2800, Hungary
  • Veszprem, 8200, Hungary
  • Zalaegerszeg, 8900, Hungary
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2005, a primary completion of Aug 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2015, 2 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2015
First posted
Oct 7, 2015
Start
Jul 2005
Primary completionActual
Aug 2013
CompletionActual
Aug 2013
Results first posted
Dec 10, 2015
Last update
Dec 10, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02569996
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Oct 7, 2015
Start date
Jul 2005
Primary completion
Aug 2013
Completion
Aug 2013
Results posted
Dec 10, 2015
Last update
Dec 10, 2015

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rituximab

Start the discussion